Levi & Korsinsky Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SKYE

Core Viewpoint - Skye Bioscience, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 4, 2024, and October 3, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2] - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]